*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Walter Rich
Summary Sentence: James Hoying, Chief Scientist, Advanced Solutions Life Sciences
Full Summary: No summary paragraph submitted.
GTMI Lunch and Learn Series Banner Image
James Hoying, Ph.D.
Chief Scientist
Advanced Solutions Life Sciences
MEETING LINK: https://primetime.bluejeans.com/a2m/live-event/tfkuwkfw
Abstract:
At present, fabricated tissues, whether for academic, industry, or clinical use, are manufactured one at a time by hand in a laboratory setting. Commercial-level production of even simple tissues (e.g. cells on a scaffold), much less tissues with more complex architectures and multiple components (e.g. with a vasculature), require more effective biomanufacturing solutions which will ultimately depend on automated, flexible fabrication approaches. Using our BioAssembly® biofabrication platform, we are developing robotic workflows to fabricate a variety of vascularized tissues and tissue models, including thick, high-cell density systems. Our strategies involve the integration of 3D printing and other fabrication methods with robotic controls to design, fabricate, and analyse these tissue models in a semi-automated fashion. Importantly, due to the critical importance of the vasculature in tissue function, we are incorporating autologous living, microvasculatures within these tissues and tissue models by recapitulating native microvessel dynamics in a controlled manner. Our vascularization approach is to enable not only the generation of individual microvessel elements, but also the remodeling of these new elements into a properly organized microvascular network functionally matched to the specific tissue. With this fabrication and vascularization technology stack, we are bringing forth protocols for liver, bone, pancreas, and other tissues that we envision technicians and clinicians, utilizing geometry- and patient-specific data, fabricating bespoke tissues easily, consistently, and to scale.
Bio:
James (Jay) Hoying is a Partner and Chief Scientist with Advanced Solutions Life Sciences with more than 25 years of experience in basic and applied biological sciences with a focus in the tissue biology and tissue vascularization. Previously, he was Professor and Chief of the Division of Cardiovascular Therapeutics at the Cardiovascular Innovation Institute (CII) where he developed a broad background in tissue fabrication, cell therapeutics, and translation of discoveries to industry and the clinic. Dr. Hoying is an inventor of the AngiomicsTM microvessel technology and holds numerous patents related to vascularizing tissues and related cell-based therapies. He is one of the first to publish in the area of vascularized tissue model fabrication using bioprinting. Dr. Hoying received his BA and MS degrees in Biology and Molecular Biology from Case Western Reserve University and his PhD in Cardiovascular Physiology, with an emphasis on the microcirculation, from the University of Arizona. Following this, Dr. Hoying served as a New Investigator in the National Institutes of Health Program of Excellence in Molecular Biology of the Heart and Lung (POEMB) in the Department of Molecular Genetics at the University of Cincinnati. Dr. Hoying is also a Fellow of the American Heart Association.
